Quantum-Si Q2 2026 Earnings Report

Quantum-Si EPS Results

• Actual EPS: N/A
• Consensus EPS: -$0.13
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Quantum-Si Revenue Results

• Actual Revenue: N/A
• Expected Revenue: $0.30 million
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Quantum-Si Announcement Details

• Quarter: Q2 2026
• Date: 8/4/2026
• Time: After Market Closes
• Conference Call Date: Tuesday, August 4, 2026
• Conference Call Time: 4:30PM ET

Quantum-Si (NASDAQ:QSI) Inc. is a life sciences instrumentation company headquartered in Guilford, Connecticut, developing next-generation proteomics solutions based on semiconductor sequencing technology. The company’s core offering centers on a proprietary single-molecule protein sequencing platform that uses a silicon-based sensor chip to convert protein data into digital signals. This approach is designed to deliver high sensitivity, single-amino-acid resolution and deep proteome coverage while potentially reducing cost and complexity compared to traditional mass spectrometry methods.

Quantum-Si’s product roadmap includes the development and commercialization of an integrated system comprising instruments, consumable reagents and proprietary data analysis software. By optimizing its chemical reagents and licensing its chip technology, the company seeks to enable researchers and biopharmaceutical developers to accelerate biomarker discovery, drug target validation and translational proteomics workflows. In addition to instrument sales, Quantum-Si offers research services and collaborative programs to demonstrate its platform in key disease-area applications.

Founded in 2017 by a team of scientists and entrepreneurs combining expertise in genomics and semiconductor engineering, Quantum-Si went public through a SPAC merger in mid-2021. Since inception, the company has invested in R&D facilities in Connecticut and established collaborations with academic laboratories and industry partners across North America and Europe. Its platform represents one of the first commercial efforts to leverage semiconductor-based detection for protein sequencing and proteomics research.

Under the leadership of President and Chief Executive Officer Steven Tignanelli—formerly CTO at Illumina—Quantum-Si is guided by a management team experienced in instrument development, bioinformatics and regulatory affairs. The company continues to expand manufacturing capabilities and pursue regulatory clearances with the goal of making advanced proteomic tools broadly accessible to research institutions and pharmaceutical companies worldwide.